Effects of association of lipoperoxide nanoemulsion and cisplatinum for a cancer targeted therapy in DLD-1 human colon adenocarcinoma cells

The oxidation therapy, an unique antitumor strategy, is based on delivering excess oxidative stress or disrupting the antioxidative defense systems into tumor cells. Lipid-hydroperoxides (LOOHs) derived from polyunsaturated fatty acids, are stable intermediates of oxidative process, and at non-toxic concentrations can act as signalling transductors of ROS, modulating gene expression and cell proliferation. LOOH, from a patented olive oil, delivered by nanoemulsion formulations (NK600), evidenced cytostatic effects on DLD-1 human colon adenocarcinoma cells. DLD1 cells exposed to Cisplatinum in association with NK600 evidenced a dramatic reduction of viability for a synergic effects of treatments (Compusyn software), and just after 24 hours exposure, a marked increase in PARP cleavage and a dramatic reduction of Srx antioxidant protein confirmed the trigger of apoptotic pathway and the inhibition of proliferation, respectively. Taken together these preliminary data, it is conceivable that NK600 could be considered as adjuvant of conventional antineoplastic regimen.